Valuation: Allogene Therapeutics, Inc.

Market Cap 732M 634M 594M 542M 1.02B 69.79B 1.03B 6.99B 2.73B 34.95B 2.75B 2.69B 117B P/E 2026 *
-2.99x
P/E 2027 * -2.78x
Enterprise Value 546M 473M 443M 404M 760M 52.08B 772M 5.21B 2.04B 26.08B 2.05B 2.01B 86.96B EV / Sales 2026 *
81,866x
EV / Sales 2027 * 43.2x
Free-Float
83.53%
Yield 2026 *
-
Yield 2027 * -
1 day-1.65%
1 week+8.21%
Current month+12.24%
1 month+9.33%
3 months-8.26%
6 months+30.25%
Current year+54.02%
1 week 1.92
Extreme 1.92
2.19
1 month 1.61
Extreme 1.61
2.19
Current year 1.31
Extreme 1.31
4.46
1 year 0.99
Extreme 0.9901
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
27.86
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 01/07/2026
Director of Finance/CFO 61 16/10/2023
Chief Tech/Sci/R&D Officer 49 28/02/2025
Director TitleAgeSince
Chairman 76 01/11/2017
Director/Board Member 66 01/06/2018
Director/Board Member 49 01/11/2017
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Free

Chief Executive Officer

610,720 0.1769%
18/6/26 Free

Director

95,400 0.0276%
18/6/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-2.12%+8.21%+104.86%-48.91% 732M
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
+0.20%+34.44%+9.12%+496.97% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.48%+1.03%-16.10%-13.32% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-0.30%-9.68%+34.94%+138.08% 12.72B
Average -0.02%+9.45%+63.21%+177.65% 26.75B
Weighted average by Cap. +0.17%+10.12%+56.51%+166.23%

Financials

2026 *2027 *
Net sales 6.67K 5.78K 5.41K 4.94K 9.28K 636K 9.43K 63.68K 24.89K 319K 25.04K 24.5K 1.06M 14.59M 12.64M 11.85M 10.81M 20.32M 1.39B 20.63M 139M 54.47M 697M 54.8M 53.61M 2.32B
Net income -197M -171M -160M -146M -275M -18.82B -279M -1.88B -737M -9.42B -741M -725M -31.43B -231M -200M -188M -171M -322M -22.04B -327M -2.21B -862M -11.03B -868M -849M -36.8B
Net Debt -186M -161M -151M -137M -258M -17.71B -262M -1.77B -693M -8.87B -697M -682M -29.57B -101M -87.33M -81.82M -74.63M -140M -9.61B -142M -962M -376M -4.81B -378M -370M -16.05B
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
13/08/26 US$2.110 -0.47% 1,416,792
11/08/26 US$2.120 +0.95% 4,967,298
10/08/26 US$2.100 +4.48% 5,360,498
07/08/26 US$2.010 +2.03% 3,699,201
06/08/26 US$1.970 +1.03% 3,170,439
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2.120USD
Average target price
9.000USD
Spread / Average Target
+324.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALLO Stock